Big Pharma faces a dual quandary. To boost slowing sales at a time when there is pressure on organic growth, pharmaceutical companies will need to turn to acquisitions. Unfortunately for several players, their resources to execute such transactions have grown more constrained than ever.
Indeed, anticipating new growth in the industry felt a lot like waiting for spring this year in the northeastern US:...